Navigation Links
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Date:7/31/2009

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhibitor of HCV.

PSI-7851 Phase 1 Multiple Ascending Dose Study Overview

In June 2009, Pharmasset initiated a phase 1 multiple ascending dose study with PSI-7851. The trial was conducted at two US centers, as a blinded, randomized, and placebo-controlled study, in 30 patients chronically infected with HCV genotype 1. The primary objective was to assess the safety, tolerability, and pharmacokinetics of PSI-7851 after once-daily (QD) dosing for 3 days. The secondary objective was to assess antiviral activity by measuring the change in HCV RNA. Patients were randomized to receive either PSI-7851 (8 patients per cohort) or placebo (2 patients per cohort). Three dose cohorts of PSI-7851 (50mg QD, 100mg QD, 200mg QD) were evaluated.

PSI-7851 Antiviral Activity Summary 

    Preliminary Antiviral Response Observed Following PSI-7851 Administered as
                                 Monotherapy for 3 Days
    --------------------------------------------------------------------------
    Dose                 N                     Mean Change in HCV RNA at Day 3
                                                            (Log(10))
    --------------------------------------------------------------------------
    50mg QD              8                                   -0.49
    100mg QD             8                                   -0.61
    200mg QD             8                                   -1.01
    Placebo              6                             
'/>"/>
SOURCE  Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  This year alone, The Leukemia & Lymphoma Society ... one goal in mind: Discovering lifesaving therapies for blood ... a flagship LLS fundraising campaign and the world,s first ... landmark 25 th anniversary. To date, TNT has ... to discover and deliver breakthrough cancer treatments that are ...
(Date:6/19/2013)... Pharma IQ is pleased to announce the release ... results from an industry survey conducted earlier this year. ... would be an area of active investment in the next ... more clinical trials in the BRIC region. The infographic, created ... Summit explores the latest trends, challenges and opportunities ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 4, 2011 Eli Lilly and Company (NYSE: ... studies of molecules that target genetic mutations and disable ... studies evaluated two unique molecules – a JAK2 inhibitor ... the American Association for Cancer Research (AACR) 102nd Annual ...
... announcing that it entered into an agreement with Oman Pharmaceutical ... Neomycin Sulfate Tablets. Under the terms of the agreement, the ... distributed by Breckenridge on an exclusive basis in the United ... and Drug Administration (FDA), and the companies began shipping the ...
Cached Medicine Technology:Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 2Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 3Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 4
(Date:6/19/2013)... Philadelphia, Pa. (June 19, 2013) The results of ... issue of Neurosurgery , official journal of the ... is published by Lippincott Williams & Wilkins , ... One study indicates that continuous "machine learning" using artificial ... survival in patients with advanced brain cancers. Another study ...
(Date:6/19/2013)... as many emergency department visits if their primary care ... days a week, according to new research from child ... Hopkins University. , The new study was published online ... and will be presented at the AcademyHealth Annual Research ... understanding where primary care practices and medical home programs ...
(Date:6/19/2013)... release is available in Spanish . ... of neglected diseases, it goes by the name of the ... was devoted to conditions that accounted for 90 per cent ... imbalance that the Drugs for Neglected Diseases initiative (DNDi) came ... the organization has been granted the BBVA Foundation Frontiers of ...
(Date:6/19/2013)... encounters are increasingly common on college campuses, but ... "hook up"? A new study by researchers with ... Medicine, published online by the Archives of ... and behaviors associated with sexual hookups, particularly among ... for negative emotional and physical health outcomes as ...
(Date:6/19/2013)... 2013 The Movement Disorders ... psychiatrists and urologists with specialists in physical therapy, ... with patients and their family members to manage ... life. Patients also have the opportunity to participate ... , “Movement disorders can be relentlessly progressive and ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Why are some college students more likely to 'hook up'? 2Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
... Until now, the mode of action of nitrogen-containing bisphosphonate ... to prevent skeletal complications in bone metastasis, has been ... access journal Genome Biology have used ,barcoded, ... the cellular response to N-BPs, opening up opportunities for ...
... , , [Vanderbilt has a 24/7 video and audio ... NASHVILLE, Tenn., Sept. 9 The following is being issued by ... care advisor, Professor of Education and Human Development , Turner, an ... the office of presidential candidate Barack Obama as a Robert Wood Johnson ...
... , , A Center for Public Accountability ... pattern of financial abuses at Tarzana Treatment Center , ... submitted an investigative report to the office of Attorney General Jerry ... may have diverted, or allowed the diversion of, up to $22 ...
... , , , ... a leading provider of kidney care services for those diagnosed with ... treatment options based on optimal patient care standards and social circumstances. ... Victor Tlatelpa, 16, is not your everyday student at ...
... Harvard School of Public Health (HSPH) and Brigham and Women,s ... sexually transmitted infection, Trichomonas vaginalis , and ... The study appears online on September 9, 2009, on the ... will appear in a later print edition. "Prostate cancer ...
... , , CAMARILLO, Calif., Sept. ... National Science Foundation (NSF) recently honored Dr. Blake Gillespie, Assistant ... Development (CAREER) award. , , The ... and research in protein-ligand interactions and biomolecular dynamics, is supported ...
Cached Medicine News:Health News:Vanderbilt Experts For Health Care Debate 2Health News:SEIU Local 721 Calls for Attorney General to Investigate Self-Dealing and $22 Million in Extra Costs at Tarzana Treatment Center 2Health News:DaVita's Patient-Centric Modalities Offer Students with Kidney Disease More Choices 2Health News:Link found between common sexual infection and risk of aggressive prostate cancer 2Health News:CI Faculty Member Awarded Nearly $1 Million NSF Grant 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
The Bair Hugger Model 505 provides safe, quiet and effective warming to patients around the world....
... has it's temperature set by means ... pressing a button. A green LED ... a flashing amber LED indicates the ... A red LED and an audible ...
Medicine Products: